UK MHRA expands Cosentyx use in paediatric arthritic conditions
The UK Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Novartis’ Cosentyx (secukinumab) in two types of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), and juvenile psoriatic arthritis (JPsA). The drug is approved alone or in combination with methotrexate (MTX) in… Read More